|Bid||18.00 x 1300|
|Ask||18.08 x 800|
|Day's range||17.26 - 18.75|
|52-week range||3.90 - 33.95|
|Beta (5Y monthly)||-2.39|
|PE ratio (TTM)||N/A|
|Earnings date||10 Mar 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||35.86|
Humanigen, Inc. today reported financial results for the first quarter ending March 31, 2021 and provided a regulatory update on lenzilumab.
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
How far off is Humanigen, Inc. ( NASDAQ:HGEN ) from its intrinsic value? Using the most recent financial data, we'll...